First Time Loading...

Abbott Laboratories

Watchlist Manager
Abbott Laboratories Logo
Abbott Laboratories
Price: 104.51 USD +0.44% Market Closed
Updated: Dec 11, 2023

Intrinsic Value

Valuation History
Abbott Laboratories

Historical Profit
Current Valuation
Price & Value Correlation
Value CAGR
Intrinsic Value History...

Our system is conducting in-depth analyses to map out the stock's valuation journey. Thank you for waiting.

Fundamental Analysis

2023-Q3 Earnings Call
Artifical Intelligence Analysis

Abbott's Strong Q3 Led by Organic Growth
Abbott's Strong Q3 Led by Organic Growth

Abbott reported a solid third quarter with an adjusted earnings per share of $1.14 and revised full-year guidance to $4.42 to $4.46, reflecting confidence in the year's strong finish. The company experienced double-digit organic sales growth across all four major business segments, excluding COVID testing. Pediatric nutrition soared with a 25% increase based on U.S. market share gains, while adult nutrition grew 12% on robust demand. Established pharmaceuticals rose 11%, led by growth in cardiometabolic, women's health, and CNS pain management, including new agreements to commercialize biosimilars in emerging markets. Core lab diagnostics excluding COVID tests grew 10%, with rapid diagnostics also seeing double-digit growth. Medical devices surged nearly 15%, fueled by FreeStyle Libre's 28% increase in sales to $1.4 billion. Expected low double-digit organic sales growth, barring COVID testing sales, sets a positive tone for the remainder of the year.


Balance Sheet Decomposition
Abbott Laboratories

Current Assets 22.7B
Cash & Short-Term Investments 7B
Receivables 6.5B
Other Current Assets 9.1B
Non-Current Assets 49.4B
Long-Term Investments 788m
PP&E 9.6B
Intangibles 32.6B
Other Non-Current Assets 6.5B
Current Liabilities 13B
Accounts Payable 4B
Accrued Liabilities 6.8B
Other Current Liabilities 2.3B
Non-Current Liabilities 21.6B
Long-Term Debt 14.5B
Other Non-Current Liabilities 7.1B
Fundamental Scores

ABT Profitability Score
Profitability Due Diligence

Abbott Laboratories's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Year Average ROE
Positive Operating Income

Abbott Laboratories's profitability score is 60/100. The higher the profitability score, the more profitable the company is.

ABT Solvency Score
Solvency Due Diligence

Abbott Laboratories's solvency score is 66/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Low D/E
Long-Term Solvency
Short-Term Solvency

Abbott Laboratories's solvency score is 66/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ABT Price Targets Summary
Abbott Laboratories

Wall Street analysts forecast ABT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ABT is 118.42 USD with a low forecast of 101 USD and a high forecast of 139.65 USD.

Price Target
101 USD
3% Downside
Price Target
118.42 USD
13% Upside
Price Target
139.65 USD
34% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape


ABT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ABT Return Decomposition
Main factors of price return

What is price return decomposition?

ABT Price
Abbott Laboratories

1M 1M
6M 6M
1Y 1Y
3Y 3Y
5Y 5Y
10Y 10Y
Annual Price Range
52w Low
52w High
Price Metrics
Average Annual Return 20.2%
Standard Deviation of Annual Returns 15.66%
Max Drawdown -35%
Shares Statistics
Market Capitalization 181B USD
Shares Outstanding 1 736 060 032
Percentage of Shares Shorted 0.7%

ABT News

Last Video News
Abbott Laboratories

Other Videos

Last Important Events
Abbott Laboratories

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.


Sentiment Analysis
Abbott Laboratories

Last 7 Days
Last 30 Days
Last 90 Days

Company Profile

Abbott Laboratories Logo
Abbott Laboratories


United States of America


Health Care

Market Cap

181B USD

Dividend Yield



Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. The company is headquartered in Abbott Park, Illinois and currently employs 113,000 full-time employees. The firm operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women’s health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.


100 Abbott Park Rd




113 000


Chairman, Pres & CEO
Mr. Robert B. Ford
Exec. VP of Fin. & CFO
Mr. Robert E. Funck Jr.
Exec. VP, Gen. Counsel & Sec.
Mr. Hubert L. Allen
Exec. VP and Group Pres of Established Pharmaceuticals & Nutritional Products
Mr. Daniel Gesua Sive Salvadori
Exec. VP of Rapid & Molecular Diagnostics
Ms. Andrea F. Wainer
VP of Investor Relations, Licensing & Acquisitions
Mr. Scott Michael Leinenweber
Show More
VP and Chief Ethics & Compliance Officer
James E. Young
VP of Public Affairs & Corp. Marketing
Ms. Melissa Brotz
Sr. VP and Chief Marketing & External Affairs Officer
Ms. Elaine R. Leavenworth
Exec. VP of HR
Ms. Mary K. Moreland
Show Less

See Also

Discover More
What is the Intrinsic Value of one ABT stock?

The intrinsic value of one ABT stock under the Base Case scenario is 91.86 USD.

Is ABT stock undervalued or overvalued?

Compared to the current market price of 104.51 USD, Abbott Laboratories is Overvalued by 12%.